Physician profile
Harry Brown
NPI 1144877978
$9,229.65
in general payments reported to CMS, 2019-2025
26 companies · $1,868 in 2025
The $1,868 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,628 · 2022: $1,430 · 2023: $1,850 · 2024: $1,455 · 2025: $1,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,012 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,011.89 |
| Education | $160.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,627.45 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,297.31 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $1,068.35 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $1,054.41 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $805.07 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $629.36 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $620.02 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $381.07 | 2022-2025 | Spravato, Invega, Invega Sustenna |
| Axsome Therapeutics, INC. | $287.50 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $271.38 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $175.82 | 2021-2023 | Trintellix |
| Corium, LLC | $175.60 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $167.12 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $105.60 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $99.57 | 2023-2025 | Qelbree, Qelbree |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $98.76 | 2021 | |
| Merck Sharp & Dohme LLC | $97.70 | 2024-2025 | Pifeltro, Delstrigo |
| Lundbeck LLC | $82.71 | 2022-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Indivior INC. | $52.06 | 2021-2022 | |
| Viiv Healthcare Company | $34.33 | 2024 | Apretude |
| Exact Sciences Corporation | $20.07 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $18.23 | 2025 | Freestyle Libre |
| Collegium Pharmaceutical, INC. | $18.16 | 2025 | Jornay Pm |
| Braeburn INC. | $16.10 | 2025 | Brixadi |
| Novo Nordisk INC | $14.03 | 2021 | |
| Eisai INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.